E2

NTDs Are Now A Human-Rights Issue. Budgets Must Follow.

Europe Can Forecast Vibrio Risk. It Still Has To Act.

Cardiology has too many dashboards. The danger is forgetting the patient

GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up

Europe Opens the SMA Gene-Therapy Door Wider

Pregnancy complications demand long-term cardiovascular care

MENA’s cardiometabolic crisis is a stability issue

Mpox Reached Guinea-Bissau. Stigma Must Not Win.

Global cardiovascular policy shifts accelerate, but diverging strategies expose uneven progress
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
